teclistamab

Home
Ligands
teclistamab

GtoPdb Ligand ID: 12233

Synonyms: JNJ-64007957 | teclistamab-cqyv | Tecvayli®

teclistamab is an approved drug (EMA & FDA (2022))

Comment: Teclistamab (JNJ-64007957) is a bispecific IgG4 monoclonal antibody that simultaneously engages CD3 on the surface of T cells, and B-cell maturation antigen (BCMA) that is expressed on the surface of multiple myeloma (MM) cells, to induce a T cell-mediated cytotoxic immune response against the BCMA +ve cells [2].

Summary
Biological activity
Clinical data
References

Bioactivity Comments
Teclistamab induces T cell-mediated cytotoxicity against BCMA +ve cell lines and MM cells from patients in vitro, but not against BCMA -ve cells [2]. It is interesting to note that cytotoxic potency of teclistamab against BCMA +ve cells was elevated in the presence of the γ secretase inhibitor LY-411575 (which reduces shedding of BCMA from the cell surface).

Bioactivity Comments

Teclistamab induces T cell-mediated cytotoxicity against BCMA +ve cell lines and MM cells from patients in vitro, but not against BCMA -ve cells [2]. It is interesting to note that cytotoxic potency of teclistamab against BCMA +ve cells was elevated in the presence of the γ secretase inhibitor LY-411575 (which reduces shedding of BCMA from the cell surface).